Antidepressants versus placebo for the treatment of bulimia nervosa: A systematic review

Australian and New Zealand Journal of Psychiatry

Volumn 34, Issue 2, 2000, Pages 310-317

  Bacaltchuk, Josue ^a   Hay, Phillipa ^b   Mari, Jair Jesus ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antidepressants; Bulimia nervosa; Meta analysis; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BULIMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BULIMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PATIENT DROPOUTS; TREATMENT OUTCOME;

EID: 0034029322     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2000.00709.x     Document Type: Conference Paper

References (48)

1. Wolfe BE. Dimensions of response to antidepressant agents in bulimia nervosa: a review. Archives of Psychiatric Nursing 1995; 9:111-121.
2. Russell GFM. Bulimia nervosa: an ominous variant of anorexia nervosa. Psychological Medicine 1979; 9:429-448.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edn. Washington: American Psychiatric Press, 1980.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edn (Revised). Washington: American Psychiatric Press, 1987.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington: American Psychiatric Press, 1994.
6. World Health Organization. The ICD-10 classification of mental and behavioral disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
7. Mulrow CD, Oxman AD, eds. Cochrane collaboration handbook. Available in the Cochrane Library [Database on Disk and CDROM]. The Cochrane Collaboration. Issue 3. Oxford: Updated Software, 1996. London: BMJ Publishing, 1996.
8. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995; 273:408-412.
9. Buchan IE. Arcus Quickstat Biomedical for Windows. Cambridge: Research Solutions, 1997.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
11. Cook RJ, Sachett DL. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 1995; 310:452-454.
12. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, 1985.
13. Cohen J. Statistical power for the behavioral sciences. 2nd edn, Hillsdale, NJ: Lawrence Erlbaum, 1988.
14. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge, MA: Harvard University Press, 1984.
15. Rosenthal R. The 'file drawer problem' and the tolerance for null results. Psychological Bulletin 1979; 86:638-641.
16. Fluoxetine Bulimia Ncrvosa Collaborative Study Group (FBNCSG). Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Archives of General Psychiatry 1992; 49:134-147.
17. Goldstein DJ, Wilson MG, Thomson VL, Potvin JH, Rampey AH Jr. Long-term fluoxetine treatment of bulimia nervosa. British Journal of Psychiatry 1995; 166:660-666.
18. Mitchell JE, Pyle RL, Eckert ED, Hatukami D, Pomeroy C, Zimmerman R. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Archives of General Psychiatry 1990; 47:149-157.
19. Rothschild R, Quitkin HM, Quiktin FM et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Imernational Journal of Eating Disorders 1994; 15:1-9.
20. Walsh BT, Hadigan CM, Devlin MJ, Gladis M, Roose SP. Long-term outcome of antidepressant treatment for bulimia nervosa. American Journal of Psychiatry 1991; 148:1206-1212.
21. Agras WS, Dorian B, Kirkley BG, Arnow B, Bachman J. Imipramine in the treatment of bulimia: a double-blind controlled study. International Journal of Eating Disorders 1987; 6:29-38.
22. Horne RL, Ferguson JM, Pope HG Jr et al. Treatment of bulimia with bupropion: a multicenter controlled trial. Journal of Clinical Psychiatry 1988; 49:262-266.
23. Mccann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. American Journal of Psychiatry 1990; 147:1509-1513.
24. Mitchell JE, Groat R. A placebo-controlled double-blind trial of amitriptyline in bulimia. Journal of Clinical Psychopharmacology 1984; 4:186-193.
25. Pope HG Jr, Hudson JI, Jonas JM, Yurgelum-Todd D. Bulimia treated with imipramine: a placebo-controlled, double-blind study. American Journal of Psychiatry 1983; 140:554-558.
26. Pope HG, Keck PE, Mcelroy S, Hudson JI. A placebo-controlled study of trazodone in bulimia nervosa. Journal of Clinical Psychopharmacology 1989; 9:254-259.
27. Walsh BT, Gladis M, Roose SP, Siewart JW, Glassman AH. Phenelzine vs placebo in 50 patients with bulimia. Archives of General Psychiatry 1988; 45:471-475.
28. Kennedy SH, Piran N, Warsh JJ et al. A trial of isocarboxazid in the treatment of bulimia nervosa. Journal of Clinical Psychopharmacology 1988; 8:391-396.
29. Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D'souza JD, Lofchy J. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of braforamine. Journal of Clinical Psychopharmacology 1993; 13:415-422.
30. Sabine EJ, Yonace A, Farrington AJ, Barrant KH, Wakeling A. Bulimia nervosa: a placebo-controlled double-blind therapeutic trial of mianserin. British Journal of Clinical Pharmacology 1983; 15:195-202.
31. Kanerva R, Rissanen A, Sarna S. Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa. Nordic Journal of Psychiatry 1994; 49:237-242.
32. Corcos M, Flament M, Atger F, Jeammet P. Traitement pharmacologique de la bulimie. L'Encephale 1996; 22:133-142.
33. Foreyt JP, Poston WSC, Goodrick GK. Future directions in obesity and eating disorders. Addictive Behaviours 1996; 21:767-778.
34. Hsu LKG. Outcome of bulimia nervosa. In: Browel KD, Fairburn CG, ed. Eating disorders and obesity. A comprehensive handbook. New York: Guillford, 1995.
35. Shaw B, Garfinkel PE. Problems of research on eating disorders. International Journal of Eating Disorders 1990; 5:545-555.
36. Wilson GT. Empirically validated treatments as a basis for clinical practice. Problems and prospects. In: Hayes SC, Follette VM, Risley T, Dawes RD, Grady K, eds. Scientific standards of psychological practice: issues and recommendations. Reno: Context, 1995:163-196.
37. Bacaltchuk JB, Hay P, Trefiglio R, Mari JJ. Antidepressants versus psychotherapy for the treatment of bulimia nervosa. Paper presented at the Sixth International Cochrane Colloquium, Baltimore, Maryland, 1998.
38. Bacaltchuk JB, Trefiglio R, Oliveira IR, Lima MS, Mari JJ. Antidepressants versus psychotherapy for bulimia nervosa: a systematic review. Journal of Clinical Pharmacy and Therapeutics 1999; 24:23-31.
39. Pyle RL, Mitchell JE, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R. Maintenance treatment and 6-month outcome for bulimic patients who respond to initial treatment. American Journal of Psychiatry 1990; 147:871-875.
40. Fichter MM, Krüger R, Rief W, Holland RD, Döhne J. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating specific psychopathology. Journal of Clinical Psychopharmacology 1996; 16:9-18.
41. Lima MS, Montcrieff J. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review (Cochrane review). In: The Cochrane Library. Issue 2. Oxford: Update Software, 1998.
42. Mitchell JE, Specker SM, de Zwaan M. Comorbidity and medical complications of bulimia nervosa. Journal of Clinical Psychiatry 1991; 52:13-20.
43. Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM. Treating bulimia with desipramine. A double-blind, placebo-controlled study. Archives of General Psychiatry 1986; 43:82-86.
44. Barlow J, Bloin J, Blouin A, Perez E. Treatment of bulimia with desipramine: a double-blind crossover study. Canadian Journal of Psychiatry 1988; 33:129-133.
45. Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramine and desipramine. Journal of Clinical Psychopharmacology 1988; 8:261-269.
46. Alger AS, Shwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. American Journal of Clinical Nutrition 1991; 53:865-871.
47. Marcus MD, Wing RR, Ewing L, Kern E. Medermott M, Gooding W. A double-blind placebo-controlled trial of fluoxetine plus behavioral modification in the treatment of obese binge-eaters. American Journal of Psychiatry 1990; 147:876-881.
48. Scrimali T, Grimali L, Corriere A, Grasso F, Frisone MF. La fluoxetina nel tratamento farmacologico della bulimia nervosa. Rivista Di Psichiatria 1994; 29:171-177.